Novartis Scraps ALS Drug After Phase 2 Failure, Adding to Pipeline Setbacks
NVS sits 15% above its 52-week low of $121.57.
Summary
Novartis is discontinuing VHB937/lifonebart, an experimental ALS therapy, after the ASTRALS Phase 2 trial missed both primary and secondary endpoints. This is the third pipeline setback in recent weeks, following the pelacarsen Phase III failure and the del-desiran Phase III miss in myotonic dystrophy. The ALS program was early-stage, so the financial impact is modest, but the pattern of clinical failures is eroding confidence in Novartis's R&D productivity. The company remains committed to neurodegenerative research, but investors will question the pipeline's depth. Watch for any strategic updates at the next earnings call.
At the time of this announcement, NVS was trading at $140.12 on NYSE in the Life Sciences sector, with a market capitalization of approximately $254.4B. The 52-week trading range was $121.57 to $170.46. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.